Eli Lilly has steered away from megadeals, and a big influx of cash from U.S. tax reform won’t change that. Darren Carroll, SVP of business development, thinks behemoth buys will get the biggest boost as companies bring overseas earnings home,
read moreOut of several potential buyers for Merck KGaA’s consumer health unit, one bidder has risen to the top: Nestle, which has its sights set on a bigger role in healthcare. More: Nestle takes the lead over Mylan, Reckitt in Merck
read moreNovartis brought on Pfizer executive Liz Barrett to head up its oncology outfit after Bruno Strigini’s retirement. One of her signature accomplishments: The rollout of Ibrance, a breast cancer drug among Pfizer’s biggest recent successes—and a head-to-head competitor to Novartis’
read moreWith plans for further expansion in China, Japan’s Eisai has opened a new solid dose plant there which will be able to produce 3 billion tablets a year. More: Eisai completes solid dose plant in Suzhou, China Source: fierce
read moreAs Sanofi looks to reshape itself and offload its European generics business, it’s reportedly getting some interest around the globe for an outfit that analysts believe could fetch $2 billion. More: Indian, Chinese drugmakers eye Sanofi's European generics unit for
read moreHeptares Therapeutics, the UK-headquartered wholly-owned subsidiary of Japan’s Sosei Group, has formed a new drug research and development pact with Imperial College London focused on gastrointestinal disease. More: Heptares, ICL sign gastrointestinal R&D pact Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals